Steroids After Spine Fusion Surgery
NCT04568837
Not Yet Recruiting
This trial studies how well low-dose postoperative corticosteroids (FDA approved) affect patient outcomes (patient reported outcomes, pain medication use, length of stay, major complications, and time to first bowel movement) after thoracic and/or lumbar spine fusion surgery.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/18/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Spine Fusion
Register for Updates
Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT01562405
Active Not Recruiting
It is possible that the combination of lenalidomide, dexamethasone and ACE 011 may reduce or prevent the growth of cancer cells along with improving anemia and bone lesions that sometimes occur in people with multiple myeloma. This current study is the first study combining ACE 011 with lenalidomide. In this research study, the investigators are looking for the highest dose of ACE 011 that can be given with lenalidomide and dexamethasone. The investigators will also begin to collect information... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Emory University, Atlanta, Georgia +3 locations
Conditions: Multiple Myeloma
Register for Updates
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
NCT00136435
Active Not Recruiting
The purpose of this study is to determine the safety and optimal dosing of L-asparaginase in adult patients with acute lymphoblastic leukemia (ALL) between the ages of 18 and 50 years.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/16/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +11 locations
Conditions: Acute Lymphoblastic Leukemia
Register for Updates
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
NCT02718833
Active Not Recruiting
This research study is studying a combination of study drugs as a possible treatment for relapsed and refractory Multiple Myeloma. The interventions involved in this study are elotuzumab, pomalidomide, bortezomib, dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +5 locations
Conditions: Multiple Myeloma
Register for Updates
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
NCT04176718
Recruiting
This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma. This research study involves two study drugs and two standard of care drugs. * The names of the study drugs involved in this study are: * Carfilzomib * Daratumumab * The names of the standard of c... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/14/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Relapse
Register for Updates
A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract
NCT04539548
Completed
To assess the safety of Dextenza compared to an active control, prednisolone acetate suspension, for the treatment of postoperative pain and inflammation following ocular surgery for pediatric cataract.
Gender:
ALL
Ages:
Between 0 years and 5 years
Trial Updated:
04/11/2024
Locations: Ocular Therapeutix, Aurora, Colorado +13 locations
Conditions: Cataract
Register for Updates
Comparison of Analgesic Efficacy Between of Interscalene Block With Liposomal Bupivacaine With Bupivacaine and Dexamethasone
NCT03969875
Completed
Pain management after shoulder surgeries poses a unique challenge to the surgeon as well as the anesthesiologist. Regional anesthesia in the form of interscalene approach to the brachial plexus as an adjunct to general anesthesia or as a sole primary technique comes to one's rescue. Interscalene block either as single shot or as a catheter is an established modality for effective analgesia which facilitates early mobilization helping in physical therapy and early discharge. With the help of loc... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/10/2024
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Total Shoulder Arthroplasty, Shoulder Osteoarthritis
Register for Updates
One Year Trial Evaluating Safety of Ozurdex With Eylea
NCT03984110
Completed
One Year Trial Evaluating Safety of Ozurdex With Eylea (COED)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Texas Retina Associates, Dallas, Texas
Conditions: Diabetic Macular Edema
Register for Updates
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
NCT01979536
Completed
This partially randomized phase II trial studies how well brentuximab vedotin or crizotinib and combination chemotherapy works in treating patients with newly diagnosed stage II-IV anaplastic large cell lymphoma. Brentuximab vedotin is a monoclonal antibody, called brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in targeted way and delivers vedotin to kill them. Crizotinib and methotrexate may stop the growth of cancer cells by blocking som... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
04/04/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama +153 locations
Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Register for Updates
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
NCT04407442
Terminated
This phase II trial studies how well daratumumab, azacitidine, and dexamethasone work in treating patients with multiple myeloma that has come back (recurrent) or has not responded to treatment (refractory) and was previously treated with daratumumab. Daratumumab is an antibody made up of immune cells that attaches to a protein on myeloma cells, called cluster of differentiation 38 (CD38). CD38 is found in higher levels on tumor cells than on normal cells. Daratumumab prevents the growth of tumo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Register for Updates
Comparing the Effects of Different Doses of Dexamethasone to Treat Inpatient COVID-19
NCT04707534
Completed
This open label clinical trial is to evaluate two different doses of dexamethasone on the health outcome using World Health Organization ordinal scale at day 28 in hospitalized patients with COVID-19.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: University of Oklahoma Medical Center, Oklahoma City, Oklahoma
Conditions: Covid19
Register for Updates
Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
NCT01572480
Active Not Recruiting
Background: * Multiple myeloma is a blood cancer that affects the plasma cells. These cells help produce antibodies and fight infection. Smoldering multiple myeloma (SMM) is a related condition that may develop into multiple myeloma. The current standard of care for SMM is close follow-up without treatment until multiple myeloma develops. However, researchers are studying possible treatments for SMM itself. One possible treatment involves a combination of cancer treatment drugs. * Lenalidomide... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Multiple Myeloma
Register for Updates